Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1897MR)

This product GTTS-WQ1897MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Cervical Cancer research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ1897MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6707MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DS 1024
GTTS-WQ6835MR IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DT-IL-3
GTTS-WQ3513MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAN-2401
GTTS-WQ7000MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA F-627
GTTS-WQ6799MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DS-8201
GTTS-WQ4434MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-734016
GTTS-WQ5861MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ7845MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GSK-1223249
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW